Benjamin Schattling

Title: Benjamin Schattling: Innovator in Neurodegenerative Disease Treatment

Introduction

Benjamin Schattling is a notable inventor based in Hamburg, Germany. He has made significant contributions to the field of neurodegenerative disease treatment through his innovative research and development efforts. His work focuses on compounds that inhibit the TRPM4 ion channel, which plays a crucial role in various neurodegenerative conditions.

Latest Patents

Schattling holds a patent for a method of treating or preventing neurodegeneration. This invention relates to a compound that effectively inhibits the function of the TRPM4 ion channel. The patent outlines the use of such compounds in treating or preventing diseases like Multiple Sclerosis, Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis. Additionally, the invention includes a pharmaceutical composition comprising a TRPM4 inhibitory compound and in vitro methods for identifying pharmaceutically active compounds useful for treating neurodegenerative diseases. He has 1 patent to his name.

Career Highlights

Benjamin Schattling is currently associated with Reprise Pharmaceuticals, Inc., where he continues to advance his research in neurodegenerative diseases. His work is pivotal in developing new therapeutic strategies that could potentially improve the quality of life for patients suffering from these debilitating conditions.

Collaborations

Some of his notable coworkers include Manuel Friese and Karin Steinbach. Their collaborative efforts contribute to the innovative environment at Reprise Pharmaceuticals, Inc., fostering advancements in medical research.

Conclusion

Benjamin Schattling's contributions to the field of neurodegenerative disease treatment highlight the importance of innovation in medicine. His work not only addresses critical health challenges but also paves the way for future research and development in this vital area.